ACM
OCUL icon

Atika Capital Management’s Ocular Therapeutix OCUL Stock Holding History

Atika Capital Management’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-220,000
Closed -$1.43M – 104
2018
Q1 		$1.43M Buy
+220,000
New +$1.24M 0.49% 64

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

Atika Capital Management's OCUL Position: Q2 2018 in Review

Atika Capital Management sold out of Ocular Therapeutix (OCUL) in Q2 2018, closing a stake of 220,000 shares — an estimated $1.43M sold.

Atika Capital Management first reported a position in OCUL in Q1 2018 and held it in 1 quarter. The position peaked at $1.43M in Q1 2018. 68 funds tracked by Wall St. Rank hold OCUL as of Q2 2018.

  • Atika Capital Management reported no remaining Ocular Therapeutix position as of Q2 2018 after selling out during the quarter.
  • Atika Capital Management sold 220,000 Ocular Therapeutix shares in Q2 2018, an estimated $1.43M.
  • Atika Capital Management first reported a position in Ocular Therapeutix in Q1 2018 and held it in 1 quarter.
  • Atika Capital Management's Ocular Therapeutix position peaked at $1.43M in Q1 2018.
  • 68 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2018.

Based on Atika Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.